On Friday, Nuvation Bio Inc (NYSE: NUVB) opened higher 0.35% from the last session, before settling in for the closing price of $2.89. Price fluctuations for NUVB have ranged from $1.22 to $4.16 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -517.71% at the time writing. With a float of $228.20 million, this company’s outstanding shares have now reached $337.57 million.
Let’s look at the performance matrix of the company that is accounted for 51 employees. In terms of profitability, gross margin is -32.69%, operating margin of -5541.88%, and the pretax margin is -21940.68%.
Nuvation Bio Inc (NUVB) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Nuvation Bio Inc is 32.40%, while institutional ownership is 43.46%. The most recent insider transaction that took place on Nov 11 ’24, was worth 162,883. In this transaction CEO, ANHEART THERAPEUTICS LTD. of this company sold 56,361 shares at a rate of $2.89, taking the stock ownership to the 3,866,228 shares. Before that another transaction happened on Oct 08 ’24, when Company’s Director bought 100,000 for $2.20, making the entire transaction worth $220,000. This insider now owns 100,000 shares in total.
Nuvation Bio Inc (NUVB) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.05 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.08) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -517.71% per share during the next fiscal year.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Check out the current performance indicators for Nuvation Bio Inc (NUVB). In the past quarter, the stock posted a quick ratio of 9.57. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 454.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.17, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of Nuvation Bio Inc (NUVB)
Nuvation Bio Inc (NYSE: NUVB) saw its 5-day average volume 2.52 million, a positive change from its year-to-date volume of 1.53 million. As of the previous 9 days, the stock’s Stochastic %D was 80.86%. Additionally, its Average True Range was 0.17.
During the past 100 days, Nuvation Bio Inc’s (NUVB) raw stochastic average was set at 45.69%, which indicates a significant decrease from 72.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.30% in the past 14 days, which was lower than the 72.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.50, while its 200-day Moving Average is $2.81. Nevertheless, the first resistance level for the watch stands at $3.02 in the near term. At $3.14, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.23. If the price goes on to break the first support level at $2.81, it is likely to go to the next support level at $2.72. The third support level lies at $2.60 if the price breaches the second support level.
Nuvation Bio Inc (NYSE: NUVB) Key Stats
There are currently 336,567K shares outstanding in the company with a market cap of 982.33 million. Presently, the company’s annual sales total 0 K according to its annual income of -75,800 K. Last quarter, the company’s sales amounted to 730 K and its income totaled -41,210 K.
